フシジン酸 (Synonyms: Fusidic acid; Fusidate; SQ-16603)

Name: Fusidic acid
Brand: MedChemExpress
SKU: HY-B1350
Rating: 5.0 (2 reviews)

製品番号: HY-B1350 純度: 99.79%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome. Fusidic acid holds promise for research in anticancer and anti-infective applications..

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

フシジン酸 構造式

CAS 番号 : 6990-06-3

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solid
100 mg	$50	在庫あり	Estimated Time of Arrival: December 31
500 mg	$110	在庫あり	Estimated Time of Arrival: December 31
1 g	$155	在庫あり	Estimated Time of Arrival: December 31
5 g	$310	在庫あり	Estimated Time of Arrival: December 31
10 g		お問い合わせ
50 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Other Forms of Fusidic acid:

Fusidic acid-d₆ 在庫あり
Fusidic acid sodium salt 在庫あり
Fusidic acid (Standard) 在庫あり

顧客検証

Antibiotic アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

Bacterial^[1]^[2]^[3]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	> 194 3 Compound: 1	Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay	10.1039/C5MD00343A
CHO	IC₅₀	>194 3 Compound: 1	Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay	10.1039/C5MD00343A
CHO	IC₅₀	194 3 Compound: 1	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
CHO	IC₅₀	194 3 Compound: 1	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
CHO	IC₅₀	>194 3 Compound: Fusidic acid	Cytotoxicity against CHO cells Cytotoxicity against CHO cells	[PMID: 28012840]
CHO	IC₅₀	> 194 3 Compound: 1	Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay	10.1039/C5MD00343A
HEK293	CC₅₀	> 32 6 Compound: FA	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
CHO	IC₅₀	194 3 Compound: 1	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
CHO	IC₅₀	> 194 3 Compound: Fusidic acid	Cytotoxicity against CHO cells Cytotoxicity against CHO cells	[PMID: 28012840]
HeLa	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
CHO-K1	IC₅₀	>194 3 Compound: 1	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability Cytotoxicity against CHOK1 cells assessed as reduction in cell viability	[PMID: 32362386]
HEK293	CC₅₀	>32 6 Compound: FA	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
MKN-45	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
U-87MG ATCC	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
HeLa	IC₅₀	>100 3 Compound: FA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
CHO-K1	IC₅₀	> 194 3 Compound: 1	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability Cytotoxicity against CHOK1 cells assessed as reduction in cell viability	[PMID: 32362386]
Vero	IC₅₀	105.8 6 Compound: Fusidic acid	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 8988597]
MKN-45	IC₅₀	>100 3 Compound: FA	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
HEK293	CC₅₀	> 32 6 Compound: FA	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
Sf21	IC₅₀	11.5 3 Compound: Fusidic acid	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	17.4 3 Compound: Fusidic acid	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
U-87MG ATCC	IC₅₀	>100 3 Compound: FA	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
Vero	IC₅₀	105.8 6 Compound: Fusidic acid	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 8988597]
HeLa	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
MKN-45	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
RAW264.7	IC₅₀	61.26 3 Compound: FA	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37544187]
Sf21	IC₅₀	11.5 3 Compound: Fusidic acid	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	17.4 3 Compound: Fusidic acid	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
U-87MG ATCC	IC₅₀	> 100 3 Compound: FA	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
Vero	IC₅₀	105.8 6 Compound: Fusidic acid	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 8988597]

体外実験

Fusidic acid (100-200 μM, 72 h) primarily inhibits the proliferation of breast cancer (MCF-7, MDA-MB-231), thyroid cancer (8505C, TPC1), and cervical cancer (Caski, HeLa) cells through cell cycle arrest rather than apoptosis^[3].
Fusidic acid (0.01-100 × MIC, 24 h) exhibits stable intracellular antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in THP-1 cells, with potency comparable to Clindamycin (HY-B1455) and Linezolid (HY-10394). MIC at pH 7.4 was 0.25 mg/L, whereas MIC at pH 5.5 decreased to 0.01 mg/L^[4].
Fusidic acid (125 mg/L, 30 min) demonstrates enhanced antibacterial activity against methicillin-sensitive Staphylococcus aureus and significantly increased intracellular accumulation under acidic conditions (pH 5.5)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:	MCF-7, MDA-MB-231 (breast cancer); 8505C, TPC1 (thyroid cancer); Caski, HeLa (cervical cancer)
Concentration:	10 μM, 100 μM, 200 μM
Incubation Time:	72 hours
Result:	Inhibited cell proliferation in a dose-dependent manner: Breast cancer cells (MCF-7: 100 μM, 28%; MDA-MB-231: 100 μM, 32%) Thyroid cancer cells (8505C: 200 μM, 43%; TPC1: 100 μM, 45%) Cervical cancer cells (Caski: 200 μM, 29%; HeLa: 200 μM, 38%)

Cell Cycle Analysis^[3]

Cell Line:	MCF-7, MDA-MB-231 (breast cancer); 8505C, TPC1 (thyroid cancer); Caski, HeLa (cervical cancer)
Concentration:	100 μM, 200 μM
Incubation Time:	72 hours
Result:	Induced different phases of cell cycle arrest depending on cell type: Breast cancer (MCF-7, MDA-MB-231): G0/G1 phase arrest (MCF-7: 200 μM, 42%; MDA-MB-231: 200 μM, 16%). Thyroid cancer (8505C, TPC1): S phase arrest (8505C: 200 μM, 12%; TPC1: 200 μM, 7%). Cervical cancer: Caski: G0/G1 increase 11%; HeLa: G2/M increase 15%.

体内実験

Fusidic acid (1 mg/mL, applied topically as a gel, 20 μL per mouse, once daily for 5 days) effectively reduced Candida albicans infection in the Cyclophosphamide (HY-17420)-induced immunosuppressed vaginal candidiasis mouse model and exhibited synergistic antifungal activity when combined with Fluconazole (HY-B0101)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cyclophosphamide (HY-17420)-induced immunosuppressed vaginal candidiasis Balb/c mouse model^[5]
Dosage:	1 mg/mL
Administration:	Vaginal gel application (VGA), 20 μL per mouse, once daily for 5 days
Result:	Significantly reduced Candida albicans CFU in vaginal lavage and fungal burden in vaginal tissue. Caused that antifungal activity was further enhanced when combined with Fluconazole (HY-B0101). Led to less vaginal tissue damage and inflammation compared to control.

臨床実験

分子量

516.71

分子式

C₃₁H₄₈O₆

CAS 番号

6990-06-3

Appearance

Solid

Color

White to off-white

SMILES

C[C@@H]([C@]1([H])CC[C@]([C@@](C[C@@H]/2OC(C)=O)3C)4C)[C@H](O)CC[C@]1(C)[C@]4([H])[C@H](O)C[C@@]3([H])C2=C(C(O)=O)/CC/C=C(C)\C

Structure Classification

Initial Source

Microorganisms

Fusidium

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (193.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9353 mL	9.6766 mL	19.3532 mL
5 mM	0.3871 mL	1.9353 mL	3.8706 mL
10 mM	0.1935 mL	0.9677 mL	1.9353 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.79%

Select Batch:

データシート (285 KB) SDS (394 KB)

COA (257 KB) HNMR (294 KB) RP-HPLC (225 KB) MS (173 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Curbete MM, et al. A Critical Review of the Properties of Fusidic Acid and Analytical Methods for Its Determination. Crit Rev Anal Chem. 2016;46(4):352-360. [Content Brief]

[2]. Payne AJ, et al. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013;112(11):3859-3863. [Content Brief]

[3]. Kim JY, et al. Growth inhibition by fusidic acid in cervical, thyroid, and breast carcinoma cell lines. Obstet Gynecol Sci. 2023 Mar;66(2):100-106. [Content Brief]

[4]. Lemaire S, et al. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis. 2011 Jun;52 Suppl 7:S493-503. [Content Brief]

[5]. Gomaa SE, et al. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model. BMC Microbiol. 2024 Feb 10;24(1):54. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9353 mL	9.6766 mL	19.3532 mL	48.3830 mL
	5 mM	0.3871 mL	1.9353 mL	3.8706 mL	9.6766 mL
	10 mM	0.1935 mL	0.9677 mL	1.9353 mL	4.8383 mL
	15 mM	0.1290 mL	0.6451 mL	1.2902 mL	3.2255 mL
	20 mM	0.0968 mL	0.4838 mL	0.9677 mL	2.4192 mL
	25 mM	0.0774 mL	0.3871 mL	0.7741 mL	1.9353 mL
	30 mM	0.0645 mL	0.3226 mL	0.6451 mL	1.6128 mL
	40 mM	0.0484 mL	0.2419 mL	0.4838 mL	1.2096 mL
	50 mM	0.0387 mL	0.1935 mL	0.3871 mL	0.9677 mL
	60 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8064 mL
	80 mM	0.0242 mL	0.1210 mL	0.2419 mL	0.6048 mL
	100 mM	0.0194 mL	0.0968 mL	0.1935 mL	0.4838 mL

Fusidic acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fusidic acid6990-06-3Fusidate SQ-16603SQ16603SQ 16603SQ-16603BacterialAntibioticbacteriostaticsteroidsgrowthelongationfactorribosomeInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

フシジン酸 (Synonyms: Fusidic acid; Fusidate; SQ-16603)

カスタマーレビュー

Other Forms of Fusidic acid:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fusidic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

フシジン酸 (Synonyms: Fusidic acid; Fusidate; SQ-16603)

カスタマーレビュー

Other Forms of Fusidic acid:

フシジン酸 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

フシジン酸 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fusidic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

フシジン酸関連抗体

フシジン酸関連抗体